Last reviewed · How we verify
TG101348
At a glance
| Generic name | TG101348 |
|---|---|
| Sponsor | TargeGen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms (PHASE2)
- Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis (PHASE2)
- Fedratinib in Combination With Nivolumab (PHASE2)
- Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (PHASE2)
- Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms (PHASE1)
- A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) (PHASE1, PHASE2)
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (PHASE2)
- A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TG101348 CI brief — competitive landscape report
- TG101348 updates RSS · CI watch RSS
- TargeGen portfolio CI